Aug 2026· Chemical Biology and Drug Design· Vol 108· 0 citations· 26 references
Medicine
TL;DR
The findings reveal that ZDHHC16 dysregulation is tissue‐specific and promotes tumor progression and modulates immune responses, highlighting its potential as a therapeutic target in several cancers, including ACC and BRCA.
Abstract
S‐palmitoylation is a crucial post‐translational modification that regulates diverse cellular processes, particularly signalling pathways. The ZDHHC family of enzymes catalyzes this modification, however, the role of ZDHHC16 in cancer warrants in‐depth investigation. This study presents a comprehensive pan‐cancer analysis of ZDHHC16, examining its expression patterns, clinical relevance, associations with immune responses, genomic characteristics, and potential as a therapeutic target. We further analysed single‐cell and spatial transcriptomic data to identify specific cell populations associated with ZDHHC16 dysregulation. Our findings reveal that ZDHHC16 dysregulation is tissue‐specific and promotes tumor progression and modulates immune responses, highlighting its potential as a therapeutic target in several cancers, including ACC and BRCA. In ACC and BRCA, high ZDHHC16 expression correlates with shorter overall survival (p < 0.001) and regulates PD‐L1 expression.
ABSTRACT 5‐Methylcytosine (m5C) is a vital RNA modification that regulates mRNA stability, splicing, and nuclear export. As a key m5C reader, ALYREF promotes tumorigenesis across various cancers; however, its precise role in endometrial cancer (EC) remains unknown. ALYREF expression and clinical significance in EC were...
Lin-Lin Hao, Jian Zhang, Qi Qian et al.· Advancement of science· 0 citations
Dimethyladenosine Transferase 1 (DIMT1) is an rRNA-modifying enzyme involved in ribosome biogenesis; however, its potential oncogenic relevance and immune-associated characteristics across human cancers remain incompletely understood. Here, we aimed to systematically characterize the biological and clinical signi...
S. Liu, Jian Yang, Min Luo· BMC Cancer· 0 citations
PCDHGB4 is a potential biomarker for pan-cancer, especially SCC, and may promote tumor progression through oncogenic signaling and modulation of the tumor immune microenvironment.
Hai-Yue Sun, Xiang Lv, Shao-Lin Liu et al.· Journal of Pharmaceutical In...· 0 citations
RNA sequencing of DRM-treated versus control rat C6 glioma cells identified 3747 differentially expressed genes, including 1660 upregulated and 2087 downregulated genes, with thrombospondin-1 markedly downregulated after DRM treatment, which may contribute to the anti-invasive effects of DRM.
Hefei Liu, Hong-Sheng Liang, Liwei Wang et al.· International Journal of Bio...· 0 citations
Cellular senescence plays a critical role in physiological and pathological processes. This study aims to elucidate the contribution of cellular senescence-related genes to disease etiology. We investigated a cohort study of 439,501 individuals, which included 22 cancers and 9 non-cancer diseases. We found that HLA-E a...
Bin Liu, Wei-Dong Wu, Chang Liu et al.· Molecular Carcinogenesis· 0 citations
PIWIL4 is a core component of the PIWI/piRNA pathway. Its roles in germ cell development, transposon silencing, and genome stability maintenance are well established. Recent studies have shown that PIWIL4 is abnormally expressed in many cancers. There, it helps regulate key malignant processes—including cell cycle cont...
Qi Deng, Yi Liu, Yang Qu et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
